Author Interviews, Cannabis / 03.02.2021

MedicalResearch.com Interview with: Benjamin J. Warnick, PhD Assistant Professor of Entrepreneurship Carson College of Business Washington State University Vancouver MedicalResearch.com: What is the background for this study? Response: Popular culture has perpetuated a notion that cannabis users are more creative. Along these lines, some successful CEOs and entrepreneurs—like Steve Jobs, for example—have claimed that cannabis use has benefitted their creativity at work. Despite such claims and increased legalization and use of cannabis, the implications of cannabis use for entrepreneurs’ creativity has yet to be rigorously tested. My coauthors and I were very intrigued to dive into the implications of cannabis use for entrepreneurs, whether good or bad. This seemed all the more relevant given the increasing legalization, destigmatization, and use of cannabis.  (more…)
Author Interviews, BMJ, Cannabis, Opiods, Yale / 29.01.2021

MedicalResearch.com Interview with: Balázs Kovács PhD Associate Professor of Organizational Behavior Yale School of Management MedicalResearch.com: What is the background for this study? Response: Our study looks at the association between the prevalence of legal cannabis stores, called “dispensaries”, and opioid-related mortality rates in the U.S.  We find that higher cannabis dispensary counts are associated with reduced opioid-related mortality rates.   We find this relationship holds for both medical dispensaries, which only serve patients who have a state-approved medical card or doctor’s recommendation, as well as for recreational dispensaries, which sell to adults 21 years and older.  The statistical associations we find appears most pronounced with the class of opioids that includes fentanyl and its analogs.  (more…)
Author Interviews, Cannabis, UCSF / 15.01.2021

MedicalResearch.com Interview with: Eric R. Pedersen, Ph.D. Adjunct Behavioral Scientist, RAND Associate Professor of Psychiatry and Behavioral Sciences Keck School of Medicine University of Southern California MedicalResearch.com: What is the background for this study? Response: In November of 2016, CA voted to legalize cannabis for sale and possession to adults 21 and older for recreational use. It wasn’t until January of 2018 that stores in most parts of LA County (we call these “outlets”) were legally able to begin selling recreational cannabis. We were collecting data from about 2,500 young adults in LA County as part of a longitudinal study (Principal Investigator Elizabeth D’Amico at RAND) and were able to look at cannabis use and intentions assessed at a period prior to the opening of the recreational cannabis outlets (pre-January 2018) to a period when those outlets were open (after January 2018). It has been suggested that once cannabis was more available for recreational purchase (and not just for medical purposes among those enrolled in CA’s medical marijuana program), use of cannabis among young adults would increase.  (more…)
Accidents & Violence, Author Interviews, Cannabis, JAMA, NYU / 23.06.2020

MedicalResearch.com Interview with: Julian Santaella Tenorio, MSc DrPH Epidemiology Center for Opioid Epidemiology and Policy Division of Epidemiology, Department of Population Health New York University Langone School of Medicine, New York, New York MedicalResearch.com: What are the main findings? car-accident-traffic-accidentResponse: This study found that recreational cannabis laws were associated with increases in traffic fatalities in Colorado (mean of 75 excess fatalities per year) but not in Washington State.  These findings suggest that unintended effects of recreational cannabis laws can be heterogeneous and may be specific to variations in how these laws are implemented
(eg, density of recreational cannabis stores).   (more…)
Author Interviews, Cannabis, Opiods / 22.06.2020

MedicalResearch.com Interview with: Amalie K. Kropp Lopez, MS MD Candidate Geisinger Commonwealth School of Medicine Class of 2023 Scranton, Pennsylvania MedicalResearch.com: What is the background for this study? Response: The opioid crisis is still affecting America, effecting millions of people from all walks of life. With the high risks of abuse and overtreatment with opioids, marijuana has been a newly reconsidered alterative for pain treatment. This study sought to quantify the changes in prescription opioid distribution using data reported by the Drug Enforcement Administration in Colorado after the legalization of recreational marijuana which gave the public increased access to its pain-relieving effects. (more…)
Accidents & Violence, Author Interviews, Cannabis, JAMA / 22.06.2020

MedicalResearch.com Interview with: Russell Kamer, MD Department of Medicine, New York Medical College, Valhalla 15 North Broadway, Suite E White Plains, NY 10601 New York MedicalResearch.com: What is the background for this study? "marijuana apocalypse - weed is a stimulant !" by Blind Nomad is licensed under CC BY 2.0Response: It is well known that marijuana usage impairs driving ability, yet the early studies of the effects of recreational marijuana legalization on traffic fatalities were inconclusive. MedicalResearch.com: What are the main findings? Response: By analyzing data over a longer time period, we found that the legalization of recreational marijuana increased traffic deaths in the first four states to legalize. Traffic fatalities increased about 20% in those states. If we apply these numbers to the nation as a whole, nationwide legalization would be associated with about 7,000 excess traffic fatalities each year. (more…)
Author Interviews, Cannabis, Emergency Care / 20.06.2020

MedicalResearch.com Interview with: Ryan Vandrey, Ph.D. Associate Professor Behavioral Pharmacology Research Unit Johns Hopkins University School of Medicine Baltimore, MD 21224  MedicalResearch.com: What is the background for this study? Response: The background for this study is that 33 states in the U.S. have legalized medicinal cannabis use and millions of people are using cannabis for therapeutic purposes, but we have very little data on the broad health impacts of medicinal cannabis use. We surveyed medicinal cannabis users and non-using controls who had a variety of health problems and found that the cannabis users reported better health, quality of life, and less healthcare utilization compared with controls.  Because we worried about group characteristics accounting for the differences observed, we then did an analysis of people who switched groups over time (e.g. non-users who later initiated cannabis use or cannabis users who later quit) and found the same differences emerged in the same individuals over time.  Important to note here is that not all individuals who used cannabis benefited from it and that most participants were using high CBD varieties of cannabis in conjunction with more traditional treatments. (more…)
Accidents & Violence, Author Interviews, Cannabis / 05.12.2019

MedicalResearch.com Interview with: Nathan J. Connealy Doctoral student John Jay College of Criminal Justice CUNY MedicalResearch.com: What is the background for this study? Response: The background, or what prompted this study, is that research on this topic is pertinent right now as more states continue down a path towards legalization. A large share of the research base and public debate centers around the potential adverse effects of marijuana accessibility, consumer-based concerns, and health specific outcomes associated with usage. This research instead focuses on a lesser explored question related to the potential for the physical dispensary locations to impact crime levels, which is also an important consideration when assessing the impact of recreational marijuana legalization. (more…)
Author Interviews, Rheumatology / 11.11.2019

MedicalResearch.com Interview with: Kelly Gavigan, MPH Manager, Research and Data Science CreakyJoints  MedicalResearch.com: What is the background for this study? Response: Over the past fifteen years, there have been significant improvements in quality of life among people living with rheumatic and musculoskeletal disease with the introduction of biologics and targeted therapies. However, despite a variety of treatments to try, patients often seek non-pharmacological alternative and complementary treatments, such as marijuana for medical use (MMU), to help manage their condition and symptoms. MMU is becoming increasingly available in the United States as different states legalize it under specific circumstances. Legal or not, according to a survey conducted by CreakyJoints using the ArthritisPower Research Registry (n=1,059 participants), people with arthritis are trying marijuana for medical use.  (more…)
Author Interviews, Cannabis, JAMA, UCSD / 23.10.2019

MedicalResearch.com Interview with: John W. Ayers, PhD, MA Vice Chief of Innovation | Assoc. Professor Div. Infectious Disease & Global Public Health University of California San Diego MedicalResearch.com: What is the background for this study? Response: Touted as a “cure all,” researchers have documented unfounded claims that  cannabidiol (CBD) treats acne, anxiety, opioid addiction, pain, and menstrual problems. You can buy CBD droplets, massage oils, CBD gummies, or even ice cream. But public health leaders have been mostly silent on the subject because they lacked data that demonstrates just how popular CBD is and the future trajectory might be. To fill this data-gap we analyzed Google search queries that mentioned “CBD” or “cannabidiol” emerging from the United States from January 2004 through April 2019 and forecasted searches through December 2019. Rather than relying on self reports, where some might not be willing to discuss CBD openly, our strategy allowed us to directly observed millions of instances of people seeking out information or even shopping for CBD online. (more…)
Author Interviews, Cannabis, JAMA / 05.10.2019

MedicalResearch.com Interview with: Hongying (Daisy) Dai, PhD Associate Professor Department of Biostatistics | College of Public Health University of Nebraska Medical Center  MedicalResearch.com: What is the background for this study? Response: Although marijuana is still classified as a Schedule I drug at the Federal level, as of June 2019, 33 states and the District of Columbia have legalized one or more forms of marijuana; 11 states and the District of Columbia have approved both medical and recreational uses. Public opinion on marijuana has changed dramatically over the last two decades and support for legalization has doubled since 2010. However, very little is known about the prevalence and patterns of marijuana use among adults with medical conditions. This study analyzed the 2016 and 2017 Behavioral Risk Factor Surveillance System data to report the prevalence and patterns of marijuana use among adults with self-reported medical conditions.  (more…)
Author Interviews, Cannabis, Columbia, Gender Differences / 06.09.2019

MedicalResearch.com Interview with: Morgan Philbin, PhD MHS Assistant Professor Department of Sociomedical Sciences Columbia University School of Public Health MedicalResearch.com: What is the background for this study? Response: Marijuana is the most frequently used substance in the United States (US) after alcohol and tobacco. In 2017, 15.3% of the US population ages 18 and up reported past-year marijuana use (MU) and 9.9% past month use. Individuals who identify as lesbian, gay, or bisexual (LGB), also report higher levels of marijuana use and marijuana use disorder than their heterosexual counterparts. Researchers have begun to explore potentially modifiable factors, such as state-level marijuana policies, that affect marijuana use and related outcomes at the population-level and within subgroups—though as of yet not among sexual minority populations. We therefore examined whether LGB individuals living in states with medical marijuana laws (MMLs) have higher levels of marijuana use and marijuana use disorder compared to LGB individuals in states without MMLs. (more…)
Addiction, Author Interviews, Cannabis, Columbia, JAMA, Opiods / 18.07.2019

MedicalResearch.com Interview with: Silvia S. Martins, MD, PHD Associate Professor of Epidemiology Department of Epidemiology Mailman School Of Public Health Columbia University  MedicalResearch.com: What is the background for this study? Response: Prior studies have suggested t6hat medical marijuana legalization might play a role in decreasing opioid use. We aimed to test this hypothesis using individual level data on nonmedical use of prescription opioids and opioid use disorder  from the US National Survey on Drug Use and Health.  (more…)
Author Interviews, Cannabis, JAMA, Pediatrics / 09.07.2019

MedicalResearch.com Interview with: D. Mark Anderson, Ph.D. Associate Professor Department of Agricultural Economics and Economics Montana State University, IZA, and NBER MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Using data from the Youth Risk Behavior Surveys for the period 1993-2017, we explore the effect medical and recreational marijuana laws have on teen use. We find that medical marijuana laws (MMLs) are not associated with teen marijuana consumption, but recreational marijuana laws (RMLs) are actually negatively associated with teen use.  (more…)
Author Interviews, Cannabis / 03.06.2019

MedicalResearch.com Interview with: Julie Bobitt, PhD Director Interdisciplinary Health Sciences College of Applied Health Sciences University of Illinois at Urbana Champaign Champaign, IL  61820 MedicalResearch.com: What is the background for this study? Response:  Older adults are using cannabis at an increasing rate but little is known about their attitudes about, and experiences – including outcomes- with, recreational and medical cannabis use. We believed a qualitative study, where we conducted focus group interviews, would provide a novel perspective to our understanding and help to identify the most salient themes concerning the use of medical and recreational cannabis by adults aged 60 and older living in Colorado. (more…)
Author Interviews, Cannabis, PLoS / 09.05.2019

MedicalResearch.com Interview with: Kyle Gardiner B.Pharm(Hons)PhD candidateDiscipline of PharmacyQueensland University of Technology | QUT · Brisbane, Australia Kyle Gardiner B.Pharm(Hons) PhD candidate Discipline of Pharmacy Queensland University of Technology | QUT · Brisbane, Australia MedicalResearch.com: What is the background for this study?   Response: The background to this study was a personal interest in behavioural science. I am often intrigued as to why health professional behave the way they do. Studies exploring health professional behaviour are seldom complete or comprehensive, however. Medicinal cannabis presents an interesting case point to explore health professional behaviours due to its topical nature. The socio-political discussion surrounding medicinal cannabis is often quite different from the medical discussion, yet for legal and regulated access to be achieved across most jurisdictions, a health professional is required to be involved in that process. Simply, if health professionals are not willing to behave, the delivery of medicinal cannabis does not occur. For purposes of transparency, I neither support or reject the use of medicinal cannabis and this paper has nothing to do improving or reducing access. This paper is about beginning to understand health professional behaviours within the context of medicinal cannabis. Yet, if we hope to change practice in the future, by definition, we need to change behaviour. We cannot change behaviour without first understanding the behaviour in context. (more…)
Author Interviews, Cannabis, Psychological Science, Social Issues, Weight Research / 24.04.2019

MedicalResearch.com Interview with: "Chocolate Brownies" by Kurtis Garbutt is licensed under CC BY 2.0. To view a copy of this license, visit: https://creativecommons.org/licenses/by/2.0Jessica S. Kruger PhD Clinical Assistant Professor Department of Community Health and Health Behavior School of Public Health and Health Professions University of Buffalo Daniel J. Kruger PhD Adjunct Faculty Associate, Population Studies Center. Michigan's Population Studies Center  MedicalResearch.com: What is the background for this study? Response: The legal environment for cannabis is changing rapidly and an increasing proportion of people are using cannabis for medical and recreational purposes. All policy and practice should be informed by science, yet there is a large gap between evidence and existing practices, and the current scope of research on cannabis users is limited. Public Health has the responsibility of protecting the public, maximizing benefits and minimizing harm in any area. However, the Public Health approach to cannabis has largely been limited to a focus on abstinence, and Federal regulations have restricted the scope of cannabis-related research. (more…)
Author Interviews, Cancer Research, Cannabis, End of Life Care, NYU / 28.03.2019

MedicalResearch.com Interview with: Arum Kim, MD Assistant Professor Medicine and Rehabilitation Medicine NYU School of Medicine Director of the Supportive Oncology Program Perlmutter Cancer Center MedicalResearch.com: What is the background for this study?   Response: There is increasing interest in medical marijuana and its applications for patients with cancers. Despite increasing access, little is known regarding doses of cannabinoids - specifically delta-8-tetrahydrocannabinol (delta-8-THC)  and cannabidiol (CBD), methods of drug delivery, and differences in patterns of use between cancer and non-cancer patients. (more…)
Accidents & Violence, Author Interviews, Cannabis / 22.02.2019

MedicalResearch.com Interview with: Lonnie M. Schaible PhD Associate Professor School of Public Affairs University of Colorado Denver, CO MedicalResearch.com: What is the background for this study? Response: Following legalization of recreational marijuana use in Colorado, strong -- but unsubstantiated -- claims were being made about crime surrounding marijuana dispensaries.  We wanted to know what the data would show.  We were especially interested in determining whether the addition of recreational facilities had any effects above and beyond those which might exist for medical dispensaries.  To better capture the dynamic landscape of marijuana legalization, this is the first study to control for the prior existence of medical dispensaries and assess how effects of both of these types of establishments changed over time. (more…)
Author Interviews, Cannabis / 25.10.2018

MedicalResearch.com Interview with: Jonathan Rothbard, MA, PhD Steinman Lab Stanford Medicine Co-founder Gold Bee – Pharmaceutical Grade CBD Products MedicalResearch.com: What is the background for this new company? How did Katexco get its name? Response: Researchers with Stanford University, Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors. Katexco will work to develop the first drug to focus on a key receptor on immune cells that are involved in inflammatory disease. The first primary target indications include gastrointestinal disorders like Crohn’s disease, gout and multiple sclerosis. Katexco is from the Greek word to restrain or regulate, and we are trying to restrain the immune system in inflammatory disease. We produce what Observer.com has ranked the #1 CBD oil for pain. In fact, our CBD oil is the best CBD oil for pain according to more than 300 independently verified reviews from consumers on TrustSpot. (more…)
Author Interviews, Cannabis, Gastrointestinal Disease / 14.08.2018

MedicalResearch.com Interview with: Beth A. McCormick, Ph.D. Professor and Vice Chair | Department of Microbiology & Physiological Systems Founding Executive Director | University of Massachusetts Center for Microbiome Research Board of Editors | Gastroenterology University of Massachusetts Medical School Worcester, MA 01655 MedicalResearch.com: What is the background for this study? What are the main findings? Response: There has been extensive, but to date mostly anecdotal, support for a beneficial role for cannabinoids and cannabis-derived agents to provide benefit for symptoms in individuals suffering from intestinal inflammatory disease (IBD). Our studies have provided one possible rationale for these previous findings: that there is a constitutively active efflux system at the luminal surface of cells that line the intestine that pumps out one class of lipids of the family known as endocannabinoids. In doing so, the intestine floods this surface with these endocannabinoids in a manner that counteracts the actions of a particular potent stimulators of intestinal inflammation that appears to be over-active in certain forms of IBD. This is most significant because a number of cannabinoids and cannabis-derived agents can mimic the actions of this class of endocannabinoids. Moreover, while cannabinoids and endocannabinoids have been shown to provide anti-inflammatory actions, these studies have identified one mechanism used by the body to localize and focus this protective function at a critical site where pro-inflammatory and anti-inflammatory events intersect, providing new insights into how to treat that imbalance in these process that occurs in certain forms of IBD. Therefore, there is the immediate opportunity to use this research to identify new therapeutic strategies to treat individuals suffering from IBD that could include either agents extracted from marijuana plants or novel molecules selected based upon superior properties made obvious by this newly defined mechanism. (more…)
Author Interviews, Cannabis, McGill, Pulmonary Disease / 30.07.2018

MedicalResearch.com Interview with: Sara Abdallah, PhD Student, first author and Dennis Jensen, PhD Associate Professor, Department of Kinesiology and Physical Education Associate Dean – Infrastructure, Faculty of Education Director, McGill Research Center for Physical Activity and Health Canada Research Chair in Clinical Exercise & Respiratory Physiology Associate Member, Translational Research in Respiratory Diseases Program Research Institute of the McGill University Health Center MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Many patients with chronic obstructive pulmonary disease (COPD) suffer from severe breathlessness at rest and on minimal exertion despite receiving optimal drug therapy for their underlying disease (e.g., bronchodilators). In these patients, breathlessness significantly diminishes exercise capacity and quality of life. Thus, research focused on identifying adjunct therapies for management of breathlessness in patients with advanced COPD is clinically relevant. A series of studies conducted in the 1970’s found that smoked cannabis caused bronchodilation (i.e., improved airway function) in healthy individuals and in patients with asthma. More recently, it has been demonstrated that delta-9 (∆9)-tetrahydrocannabinol (THC, the major cannabinoid constituent of cannabis) inhibits cholinergic contractions in isolated human bronchi and that a positive association exists between measure of lung function (e.g., forced expiratory volume in 1-sec) and cannabis use in patients with COPD. These studies lead us to hypothesize that inhalation of vaporized cannabis may alleviate exertional breathlessness and improve exercise tolerance in patients with advanced COPD by improving airway function at rest and during exercise. (more…)
Author Interviews, Brigham & Women's - Harvard, Cannabis, Pediatrics, Pediatrics / 07.11.2017

MedicalResearch.com Interview with: Shane Shucheng Wong, MD Massachusetts General Hospital Boston, Massachusetts  MedicalResearch.com: What is the background for this study? Response: Medical cannabis is now legal in 29 states and the District of Columbia, and in those areas with active programs, children and adolescents can legally access medical cannabis with certification from their doctor and consent from a parent. This means that doctors and families need to understand what we know and what we don’t yet know about medical cannabis in order to make the best decision for the health of the individual child. Two synthetic cannabinoids – compounds that act on specific receptors in the brain – have been approved for medical use in the U.S., both of which mimic a form of THC (tetrahydrocannabinol), the compound responsible for the “high” of recreational cannabis use. Dronabinol (Marinol) is approved to treat chemotherapy-induced nausea and vomiting in both children and adults, while the pediatric use of nabilone (Cesamet) carries a caution. A third cannabinoid, cannabidiol, is currently in phase 3 trials for treatment of seizures. (more…)